Pfizer to invest $650M in Groton center

Pfizer plans to invest $650 million in a new Manufacturing Technology Center at its research and development campus in Groton, Connecticut. The project involves building an approximately 220,000-square-foot facility that will support the company’s global clinical trials. The investment is scheduled to be made over the next five years and is described as a major commitment to the Groton site and the wider region.

The facility will be located within Pfizer’s existing Groton campus, which is one of the company’s major research and development centers. The campus spans more than 2 million square feet of lab and office space on 175 acres and plays a central role in clinical development, global clinical supply, drug safety, medicine design, and pharmaceutical sciences.

The new Manufacturing Technology Center is designed to produce clinical active pharmaceutical ingredients and drug products. These outputs will support Pfizer-sponsored clinical trials around the world, linking scientific discovery at Groton with advanced clinical manufacturing. Pfizer officials indicate that the center will modernize infrastructure for its existing workforce and help meet future clinical manufacturing needs.

Raja Mangipudy, Pfizer’s Groton site head, said the company has a long history of scientific innovation at the site and that the new center will advance its ability to support clinical research and develop new medicines for patients globally. Company statements emphasize that many discoveries powering Pfizer’s pipeline originate from the Groton laboratories and that nearly every Pfizer medicine is developed in part at this site.

Construction of the Manufacturing Technology Center is expected to begin in the second quarter of 2027. Pfizer targets an operational startup date in mid-2031, reflecting a long-term build-out and qualification period typical of complex pharmaceutical manufacturing facilities. The company plans to transition employees working in other parts of the Groton campus into the new building, bringing related operations under one roof.

Project plans call for consolidating existing functions rather than relying on state financial support. State officials and economic development organizations note that no state funding will be allocated for the project. The center is intended to provide a modern, purpose-built environment for clinical manufacturing activities already aligned with Groton’s research and development strengths.

Local and state leaders frame Pfizer’s investment as a strong endorsement of Connecticut’s workforce and innovation capacity. Statements from state economic development officials describe the project as reflecting confidence in the state’s life sciences talent and its broader economic strategy centered on innovation. They also highlight that such investments show Connecticut as a place where companies can invest, innovate, and grow.

Community leaders in Groton describe Pfizer’s presence as an important asset for the town and the southeastern Connecticut region. They view the new Manufacturing Technology Center as reinforcing a long-standing relationship and supporting opportunities for residents, businesses, and skilled trades. The project is characterized as a long-term commitment that keeps existing work in the area and provides years of construction activity followed by ongoing campus roles.